SCHEMBL6861535

SCHEMBL6861535

O=C(Cl)c1c[nH]c(-c2ccccc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 4/20 0.41
CYP1A2 P05177 2/20 0.41
MAPK1 P28482 1/20 0.41
CASP1 P29466 1/20 0.41
CYP2C19 P33261 1/20 0.41
RNASEH1 O60930 1/20 0.38
ERCC1 P07992 1/20 0.38
FEN1 P39748 1/20 0.38
ERCC4 Q92889 1/20 0.38
ADORA3 P0DMS8 3/20 0.37
ALDH1A1 P00352 1/20 0.37
ADORA2A P29274 2/20 0.36
F2 P00734 1/20 0.36
F12 P00748 1/20 0.36
ADORA1 P30542 1/20 0.36
MTOR P42345 1/20 0.36
ADK P55263 1/20 0.36
NISCH Q9Y2I1 1/20 0.36
PDE2A O00408 2/20 0.36
DHODH Q02127 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1080850 0.85 PIN1 (0.47) PIN1CYP1A2MAPK1CASP1CYP2C19
SCHEMBL1079995 0.84 ALDH1A1 (0.49) PIN1CYP1A2MAPK1CASP1CYP2C19
Hydrochloric Acid SCHEMBL6861539 0.84 PIN1 (0.46) PIN1CYP1A2MAPK1CASP1CYP2C19
SCHEMBL811735 0.84 MAPT (0.46) PIN1CYP1A2MAPK1CASP1CYP2C19
SCHEMBL786633 0.81 ALDH1A1 (0.46) PIN1CYP1A2MAPK1CASP1CYP2C19
SCHEMBL25413935 0.78 PIN1 (0.52) PIN1ADORA3ALDH1A1ADORA2AF2
SCHEMBL19734173 0.78 MEN1 (0.47) PIN1CYP1A2ADORA3ALDH1A1ADORA2A
SCHEMBL17321497 0.78 PIN1 (0.41) PIN1CYP1A2MAPK1CASP1CYP2C19
SCHEMBL1313241 0.78 ERCC1 (0.50) ERCC1FEN1ERCC4ALDH1A1PDE2A
SCHEMBL4414614 0.76 KMT2A (0.51) ADORA3ALDH1A1ADORA2AADORA1MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6797824-B2 UEFUL IN THE DIAGNOSIS AND THERAPY OF AFFECTIVE DISORDERS SUCH AS SCHIZOPHRENIA AND DEPRESSION AS WELL AS CERTAIN MOVEMENT DISORDERS SUCH AS PARKINSONISM NEUROGEN CORPORATION 2004-09-28 US disclosed
US-20030018025-A1 Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands NEUROGEN CORPORATION, CORPORATION OF THE STATE OF DELAWARE 2003-01-23 US disclosed
US-20020143044-A1 Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands NEUROGEN CORPORATION 2002-10-03 US disclosed
CN-1088062-C Certain 4 -aminomethyl -2 -substituted imidazole derivatives and 2 -aminomethyl -4 -substituted imidazole derivatives, new classes of dopamine receptor subtype specific ligands NEUROGEN CORP (US) 2002-07-24 CN disclosed
US-6358955-B1 SCHIZOPHRENIA, PSYCHOLOGICAL DISORDERS, PARKINSON*S DISEASE; ANTIDEPRESSANTS NEUROGEN CORPORATION 2002-03-19 US disclosed
US-6069251-A HIGHLY SELECTIVE PARTIAL AGONISTS OR ANTAGONISTS AT BRAIN DOPAMINE RECEPTOR SUBTYPES OR PRODRUGS; DIAGNOSIS AND TREATMENT SCHIZOPHRENIA; ANTIDEPRESSANTS; CERTAIN MOVEMENT DISORDERS SUCH AS PARKINSONISM. NEUROGEN CORPORATION (US) 2000-05-30 US disclosed
CN-1177349-A Certain 4 -aminomethyl -2 -substituted imidazole derivatives and 2 -aminomethyl -4 -substituted imidazole derivatives, new classes of dopamine receptor subtype specific ligands NEUROGEN CORP (US) 1998-03-25 CN disclosed
US-5712392-A DOPAMINERGIC AGENTS TREATING SCHIZOPHRENIA, ANTIDEPRESSANTS FOR PARKINSON'S DISEASE NEUROGEN CORPORATION (US) 1998-01-27 US disclosed
EP-0793653-A1 CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1997-09-10 EP disclosed
US-5656762-A TREATING SCHIZOPHRENIA, DEPRESSION, PARKINSON*S DISEASE NEUROGEN CORPORATION (US) 1997-08-12 US disclosed
US-5646281-A FOR USE IN THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA, DEPRESSION AND PARKINSON*S DISEASE NEUROGEN CORPORATION (US) 1997-07-08 US disclosed
US-5633377-A DIAGNOSIS, THERAPY OF SCHIZOPHRENIA, DEPRESSION, PARKINSON'SDISEASE NEUROGEN CORPORATION (US) 1997-05-27 US disclosed
WO-1996016040-A1 CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018025-A1 Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands CHRNA4, GRIA4, OPRM1 PIN1 3547/4885CYP1A2 377/4885MAPK1 2294/4885
US-20020143044-A1 Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands DRD2, OPRM1, OPRD1 PIN1 4219/4885CYP1A2 451/4885MAPK1 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.